Free Trial
NASDAQ:NKTX

Nkarta Q2 2024 Earnings Report

Nkarta logo
$2.20 -0.01 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.20 0.00 (0.00%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Nkarta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nkarta Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
4:00PM ET

Nkarta Earnings Headlines

Nkarta, Inc. Reports Q2 2025 Financial Results
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Nkarta (NKTX) Projected to Post Earnings on Tuesday
See More Nkarta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

View Nkarta Profile

More Earnings Resources from MarketBeat